Comparison of the effect of two HMG CoA reductase inhibitors on LDL susceptibility to oxidation

Portal, Vera Lúcia; Moriguchi, Emílio Hideyuki; Vieira, José Luiz da Costa; Schio, Sadi Marcelo; Mastalir, Eduardo T.; Buffé, Fabiana; Bortolini, Eleni Borges; Bruch, Ricardo; Rodrígues, R

doi:10.1590/s0066-782x2003000200004

Cited by 6 publications

(2 citation statements)

References 46 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, oxidative stress of different patients has been shown to decrease after treatment with atorvastatin, simvastatin, pravastatin, fluvastatin, and lovastatin [16][17][18]. In addition, treatment with these statins was followed by a prolonged lag time of LDL oxidation [19][20][21]. Statin therapy also causes a significant reduction in plasma levels of ox-LDL [17] and it has also been reported that in hypercholesterolemia or mixed type hyperlipidemia, atorvastatin can increase total plasma antioxidant status, leading to a lower LDL oxidation capacity [19].…”

Section: Discussionmentioning

confidence: 99%

Simvastatin Therapy Reduces Prooxidant‐Antioxidant Balance: Results of a Placebo‐Controlled Cross‐Over Trial

Parizadeh

Azarpazhooh

Moohebati

et al. 2011

Lipids

143

View full text Add to dashboard Cite

Oxidative stress is thought to play an important role in atherogenesis. The statin group of cholesterol-lowering drugs have been shown to reduce cardiovascular events and possess antioxidant properties. We aimed to assess the effects of simvastatin on a novel measure of prooxidant-antioxidant balance (PAB) in dyslipidemic patients. The PAB assay can measure the prooxidant burden and the antioxidant capacity simultaneously in one assay, thereby giving a redox index. We treated 102 dyslipidemic individuals with simvastatin, or a placebo in a double-blind, cross-over, placebo-controlled trial. PAB values were measured before and after each treatment period. Seventy-seven subjects completed the study. We found that statin therapy was associated with a significant reduction in PAB values (P < 0.001). This effect appeared to be independent of the cholesterol-lowering effects of statins. We conclude that serum PAB values are decreased by simvastatin therapy. Regarding previous reports on the elevation of PAB in conditions associated with oxidative stress, the PAB assay, along with other markers of oxidative stress, may be applied to estimate the extent of oxidative stress in patients, assessment of the antioxidative efficacy of medication such as statins and perhaps also for the identification of those individuals who need antioxidant therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Simvastatin Therapy Reduces Prooxidant‐Antioxidant Balance: Results of a Placebo‐Controlled Cross‐Over Trial

Parizadeh

Azarpazhooh

Moohebati

et al. 2011

Lipids

143

View full text Add to dashboard Cite

show abstract

“…It is possible that the antioxidative effect of pravastatin is not generally detected in patients with hypercholesterolemia due to the relatively high levels of oxidative stress in these patients, and that a condition of low peroxyl radical (such as after treatment with fluvastatin) is necessary for the anti-oxidative effect of pravastatin to be detected. In fact, Portal et al, who started statin treatment in hypercholesterolemic patients with CHD after a low cholesterol diet, reported that both fluvastatin and pravastatin significantly inhibited in vitro LDL oxidation induced by Cu 2+ and the water-soluble free radical initiator azo-bis (2'-2'amidinopropanil) HCl (AAPH) (19). However, it is also possible that the reduced levels of OxLDL autoantibodies after switching from fluvastatin to pravastatin are due to a carry-over effect of fluvastatin.…”

Section: Discussionmentioning

confidence: 99%

A Comparative Crossover Study of the Effects of Fluvastatin and Pravastatin (FP-COS) on Circulating Autoantibodies to Oxidized LDL in Patients with Hypercholesterolemia

Zhang

Noda

Matsunaga

et al. 2005

JAT

View full text Add to dashboard Cite

This study compared the effects of fluvastatin and pravastatin on the in vivo oxidation of LDL in a crossover design to evaluate whether or not it is justified to switch between the two statins with regard to serum levels of lipids, lipoproteins, and apolipoproteins (apo), and circulating autoantibodies to oxidized LDL (OxLDL-Ab). Patients with hypercholesterolemia (n = 46) were randomly assigned into groups who received fluvastatin (20 mg/d) or pravastatin (10 mg/d). After 3 months, they were crossed to receive the other statin for another 3 months. Circulating levels of OxLDLAb were measured by an OxLDL IgG ELISA test. Fluvastatin and pravastatin similarly decreased serum levels of total cholesterol (TC), LDL-C, and apo B, and increased HDL2-C levels. After crossover to the other statin, these lipid parameters were not further changed by either statin. Before crossover, circulating levels of OxLDL-Ab were decreased in patients with fluvastatin treatment, but not in those with pravastatin treatment. After switching from the other statin, both fluvastatin and pravastatin further decreased OxLDL-Ab levels. In conclusion, fluvastatin at 20 mg/d and pravastatin at 10 mg/d are similar with regard to their efficacy in decreasing TC, LDL-C, and apo B levels and increasing HDL2-C levels. Fluvastatin lowered circulating levels of OxLDLAb, and these effects continued after switching to pravastatin. J Atheroscler Thromb, 2005; 12: 41-47.

show abstract

Statins and foam cell formation: Impact on LDL oxidation and uptake of oxidized lipoproteins via scavenger receptors

Hofnagel

Luechtenborg

Weißen-Plenz

et al. 2007

Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biolog

View full text Add to dashboard Cite

Comparison of the effect of two HMG CoA reductase inhibitors on LDL susceptibility to oxidation

Abstract: In hypercholesterolemic patients with CHD, both fluvastatin and pravastatin reduced LDL susceptibility to oxidation.

Cited by 6 publications

References 46 publications

Simvastatin Therapy Reduces Prooxidant‐Antioxidant Balance: Results of a Placebo‐Controlled Cross‐Over Trial

Simvastatin Therapy Reduces Prooxidant‐Antioxidant Balance: Results of a Placebo‐Controlled Cross‐Over Trial

A Comparative Crossover Study of the Effects of Fluvastatin and Pravastatin (FP-COS) on Circulating Autoantibodies to Oxidized LDL in Patients with Hypercholesterolemia

Statins and foam cell formation: Impact on LDL oxidation and uptake of oxidized lipoproteins via scavenger receptors

Contact Info

Product

Resources

About